AZN Earnings Prediction
The chart below shows how AZN performed 10 days before and after its earnings report, based on data from the past quarters. Typically, AZN sees a -2.50% change in stock price 10 days leading up to the earnings, and a +1.96% change 10 days following the report. On the earnings day itself, the stock moves by +1.77%. This data can give you a slight idea of what to expect for the next quarter's release.
AZN Key Earning Data
2024/Q4
Year Over Year
Quarter Over Quarter
Total Revenue
14.89B
23.84%
9.78%
Gross Margin
81.08%
0.22%
-0.92%
Operating Margin
21.78%
56.80%
-11.79%
Net Margin
10.07%
26.19%
-4.64%
EPS
0.96
57.38%
5.49%
No Data Available
AZN Earnings Analysis
AstraZeneca PLC Corporation (AZN.O) Earnings Conference Call
Positive
Revenue Surge: Total revenue increased by 21% in 2024, demonstrating strong underlying momentum.
Core EPS Increase: Core EPS rose by 19%, reflecting effective cost management and operational efficiency.
Pivotal Trials Revenue Potential: Nine high-value pivotal trials were read out in 2024, representing over $5 billion in non-risk adjusted peak year revenue potential.
New Medicine Approvals: Eight new medicines have been approved to date, including the recent approval of Datroway, advancing the company's pipeline towards its goal of 20 new medicines by 2030.
Emerging Market Expansion: Emerging market growth reached 22% in 2024, highlighting the company's expanding presence and capabilities in these regions.
Negative
Earnings Performance Shortfall: AstraZeneca reported an EPS of $1.05, missing expectations of $1.07, indicating a shortfall in earnings performance.
Q4 Revenue Decline: China's revenue growth was impacted by a 3% decline in Q4, primarily due to year-end hospital ordering dynamics affecting key products like Tagrisso and Farxiga.
Potential Import Tax Liabilities: The company faces potential fines related to unpaid importation taxes in China, with liabilities ranging from $900,000 to $4.5 million if found liable.
China Market Concerns: Despite a 22% growth in emerging markets, the overall performance in China shows a concerning trend with a significant decline in Q4, raising concerns about future growth prospects.
China Import Tax Investigations: The ongoing investigations in China regarding importation taxes could lead to financial penalties, which may adversely affect AstraZeneca's financial stability.
AZN FAQs
How does AZN typically perform around its earnings report dates?
Is AstraZeneca PLC (AZN) Q4 2024 Earnings Call Summary positive or negative?
How can historical earnings data help predict future stock performance?
AZN Earning Call Sentiment
AstraZeneca PLC (NASDAQ:AZN) Q4 2024 Earnings Call Transcript
AZN.O
-1.22%Positive
The earnings call reveals mixed signals: strong emerging market growth and a share buyback program are positives, but issues like regulatory investigations in China, missed earnings expectations, and unclear management responses raise concerns. The upgraded guidance and strategic focus in China and emerging markets provide optimism. However, the potential fines and competitive pressures balance this out, leading to a neutral sentiment. The lack of market cap data prevents assessing potential volatility, but overall, the stock is likely to remain stable in the short term.
